Fundamental Analysis

ASTRAZENECA PHARMA 

{Ticker : 506820 { BUY: Rs. 2410.00 { Target: Rs. 2700

AstraZeneca Pharma India is a global biopharmaceutical company engaged in discovery, development and commercialisation of medicines for core areas of healthcare, including metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. On a standalone quarterly front, net sales saw a growth of 4.03 per cent to Rs 223.86 crore in the quarter ended December 2019 from Rs 215.19 crore in the quarter ended December 2018. The company reported an operating profit of Rs 40.22 crore in Q3FY20, declining 9.36 per cent from Rs 44.38 crore in Q3FY19. Similarly, net profit fell by 8.22 per cent to Rs 26.70 crore in Q3FY20 from Rs 29.09 crore in Q3FY19. In March 2020, the company received import and marketing permission in form CT-20 from Drugs Controller General of India (DCGI) for Acalabrutinib 100 mg capsules (Calquence), paving the way for its launch in India, which is likely to boost revenue. We thus, recommend a BUY.